All Stories

  1. Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy

    Article • OncoImmunology, February 2018, Taylor & Francis

    Dr. James Brugarolas

  2. Targeting Renal Cell Carcinoma with a HIF-2 antagonist

    Article • Nature, September 2016, Nature

    Dr. James Brugarolas

  3. Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma

    Article • Molecular and Cellular Biology, May 2016, ASM Journals

    Dr. James Brugarolas

  4. Platelet-Derived Growth Factor/Vascular Endothelial Growth Factor Receptor Inactivation by Sunitinib Results in Tsc1/Tsc2-Dependent Inhibition of TORC1

    Article • Molecular and Cellular Biology, July 2013, ASM Journals

    Dr. James Brugarolas